权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Tissue Regeneration by Engineered Extracellular Vesicles

工程细胞外囊泡的组织再生

基本信息

批准号：
10021673
负责人：
James D. Bryers
金额：
$ 46.01万
依托单位：
UNIVERSITY OF WASHINGTON
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-20 至 2023-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10021673
关键词：
Angiogenic Factor B-Lymphocytes Biocompatible Materials Biological Assay C57BL/6 Mouse CD19 gene CD3 Antigens Cell Line Cell Lineage Cell Therapy Cell membrane Cells Chronic Coated vesicle Communication Defect Encapsulated Engineering Epigenetic Process Ethical Issues Exhibits Fibroblasts Film Fingerprint Flow Cytometry Fluorescence Foreign Bodies Gene Expression Genetic Transcription Growth Growth Factor ITGAX gene Implant In Vitro Inflammation Knockout Mice Lipids Mass Spectrum Analysis Mediating Membrane Membrane Proteins Mesenchymal Stem Cells Messenger RNA MicroRNAs Modeling Mouse Strains Myelogenous Myeloid Cells Natural regeneration Nucleic Acids Organ Transplantation Parents Pathway interactions Phenotype Polymers Proteins Research Role Signal Transduction Somatic Cell Spinal cord injury Stains Structure Surface System T-Lymphocyte TLR1 gene Technology Testing Time Tissues Transgenic Mice Tube United States National Institutes of Health Vesicle Work Wound models angiogenesis biodegradable polymer bone culture plates cytokine embryonic stem cell engineered exosomes exosome experimental study extracellular vesicles healing in vivo injured intercellular communication macrophage microvesicles novel paracrine particle preservation proteomic signature regenerative release factor response scaffold selective expression stem cell therapy stem cells stem-like cell tissue regeneration tissue repair tissue support frame transcription factor transdifferentiation vesicular release

项目摘要

Summary Worldwide stem cell therapy market is poised to grow at a compound annual growth rate (CAGR) of 39.5% from 2015 to 2020, reaching US$330M by 2020. However, limitations such as: (1) ethical issues related to embryonic stem cells, (2) difficulties related with the preservation of stem cells, and (3) recent research findings that the structural contribution of stem cells to regenerated tissues is actually very small, are starting to compromise the promised potential of stem-cell based therapies. Recent research has thus shifted away from cell based therapy to a paracrine hypothesis, investigating the stimulating factors released and received by cells, including: growth factors, cytokines, and extracellular vesicles (EVs; i.e., exosomes and microvesicles containing angiogenic factors, transcription factors, miRNAs). Work proposed here will determine whether myeloid cells, i.e., can be engineered to differentiate (or trans-differentiate) into desired non-myeloid lineages through an orchestrated engineering of EV exchange within our novel biomaterials platform.

总结